38 slides from Galectin Therapeutics's shareholder meeting presentation, May 26, 2011
Slide 1: Annual Stockholders Meeting May 26, 2011
Annual Stockholders Meeting May 26, 2011 Exhibit 99.1
Slide 2: Forward Looking Statements
© 2011 Galectin Therapeutics 2 Forward Looking Statements This presentation contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance
Slide 3: Annual Stockholders Meeting Highlights
© 2011 Galectin Therapeutics 3 Annual Stockholders Meeting Highlights All resolutions passed Authorized Board of Directors to change name All BOD members elected BOD may expand to 11 members Increased stock incentive plan to 20,000,000 shares Ratified appointment of McGladrey & Pullen as auditor for
Slide 4: Pro-Pharmaceuticals is now Galectin Therapeutics
© 2011 Galectin Therapeutics 4 Pro-Pharmaceuticals is now Galectin Therapeutics New company name reflects our leadership in galectin science and drug development
Slide 5: Galectin Proteins Are Important In Disease Pathogenesis
© 2011 Galectin Therapeutics 5 Galectin Proteins Are Important In Disease Pathogenesis Secreted Galectin Proteins 1. Bind to cell surface and matrix glycoproteins ( galactose residues) 2. Modulate cell signaling 3. Promote cell-cell interactions 4. Promote cell- matrix interactions PROMOTE PATHOLOGY
Slide 6: Our Galectin Inhibitors Are Novel Carbohydrate-Based Drug Compounds
© 2011 Galectin Therapeutics 6 Galectin Proteins Galectin Inhibitor Our Galectin Inhibitors Are Novel Carbohydrate-Based Drug Compounds Carbohydrate-based, galactose-containing drugs that bind to and inhibit galectin proteins Target secreted galectins and those associated with cell membrane Strong b
Slide 7: We Are The Leaders In Galectin Inhibitor Drug Development
© 2011 Galectin Therapeutics 7 We Are The Leaders In Galectin Inhibitor Drug Development Only company with galectin inhibitors in clinical development Published authoritative books in the field
Slide 8: Galectins Are Involved In The Pathogenesis Of Many Diseases
© 2011 Galectin Therapeutics 8 Galectins Are Involved In The Pathogenesis Of Many Diseases Fibrosis of organs Nearly all cancers Heart failure Ischemic cardiovascular and cerebrovascular disease Arthritis Allergic disease Eczema and skin inflammation Inflammatory bowel disease Eye inflammation Infla
Slide 9: How Do We Choose Diseases For Drug Development?
© 2011 Galectin Therapeutics 9 How Do We Choose Diseases For Drug Development? Galectins are proven important in the mechanism of disease There are serious, life threatening consequences to patients There are no, few, or ineffective therapies Our drug compounds can make a major impact Treat importan
Slide 10: Strategic Approach To Drug Development
© 2011 Galectin Therapeutics 10 Strategic Approach To Drug Development Choose the right disease target and patient population Design clinical development approaches that add value to the company in shortest time possible Seek partners when development program becomes advanced and requires resources
Slide 11: Disease Area Development Programs
© 2011 Galectin Therapeutics 11 Disease Area Development Programs Cancer Fibrosis Liver Fibrosis Chemotherapy Immunotherapy GALECTINS
Slide 12: Disease Area Development Programs
© 2011 Galectin Therapeutics 12 Disease Area Development Programs Cancer Fibrosis Liver Fibrosis Chemotherapy Immunotherapy GALECTINS
Slide 13: Development Program In Liver Fibrosis
© 2011 Galectin Therapeutics 13 Galectin Therapeutics’ Development Program In Liver Fibrosis Liver fibrosis represents a very large unmet medical need Liver fibrosis and the end stage of cirrhosis is the result of all diseases that affect the liver The only available therapy is liver transplantation
Slide 14: Multiple Diseases Lead To Liver Fibrosis And Cirrhosis
© 2011 Galectin Therapeutics 14 Multiple Diseases Lead To Liver Fibrosis And Cirrhosis With Serious Medical Consequences ONLY CURRENT THERAPY FOR CIRRHOSIS IS LIVER TRANSPLANTATION Alcoholic liver disease Chronic hepatitis C Chronic hepatitis B/D Steatohepatitis (NASH) Autoimmune hepatitis Bile duct
Slide 15: Fibrosis Of The Liver Leads To Scarring (Cirrhosis)
© 2011 Galectin Therapeutics 15 Fibrosis Of The Liver Leads To Scarring (Cirrhosis) Healthy Cirrhosis
Slide 16: The Liver Fibrosis Iceberg
© 2011 Galectin Therapeutics 16 The Liver Fibrosis Iceberg Transplants (8,000*) Wait List (17,000**) Death from Cirrhosis (60,000*) Cirrhosis (450,000**) Liver Disease (25,000,000**) * Per annum in US * * Prevalence in US Huge medical problem in US and even bigger in rest of world
Slide 17: Galectin-3 Is Markedly Increased In Human Liver Cirrhosis
© 2011 Galectin Therapeutics 17 Galectin-3 Is Markedly Increased In Human Liver Cirrhosis Henderson, et al. PNAS, 103:5060-5065, 2006 Normal Human Liver Fibrotic Human Liver (Cirrhosis)
Slide 18: Fibrosis Does Not Occur In Mice Where The Galectin-3 Gene Has Been Eliminated
© 2011 Galectin Therapeutics 18 Fibrosis Does Not Occur In Mice Where The Galectin-3 Gene Has Been Eliminated Henderson, et al. PNAS, 103:5060-5065, 2006 Fibrotic Mouse Liver Gal-3 Knock Out Mouse Liver
Slide 19: The Fibrogenic Cells In Human Liver Are Regulated By Galectins
© 2011 Galectin Therapeutics 19 Fibrotic Protein The Fibrogenic Cells In Human Liver Are Regulated By Galectins Stellate Cells
Slide 20: Galectin Inhibitors Effectively Treat Liver Fibrosis in Rats
© 2011 Galectin Therapeutics 20 Galectin Inhibitors Effectively Treat Liver Fibrosis in Rats Liver Fibrosis induced by injection of chemical toxin for 8 weeks Regression of Fibrosis after 4 weeks of treatment with GR-MD-01
Slide 21: Goals For Fibrosis Program
© 2011 Galectin Therapeutics 21 Goals For Fibrosis Program Nominate optimal drug candidate to move into clinical development (Q4 2011) Submit IND to treat patients with liver fibrosis Select clinical patient population for study to enable fast track designation and seek orphan disease status
Slide 22: Disease Area Development Programs
© 2011 Galectin Therapeutics 22 Disease Area Development Programs Cancer Fibrosis Liver Fibrosis Chemotherapy GALECTINS Immunotherapy
Slide 23: Roles Of Secreted Galectins In Cancer
© 2011 Galectin Therapeutics 23 Roles Of Secreted Galectins In Cancer The vast majority of cancers secrete large amounts of galectins Tumor cell invasion: extracellular matrix adhesion & detachment Stromal cell function Metastasis: cell invasion and migration Angiogenesis Tumor immunity
Slide 24: Our Drug GM-CT-01 (DAVANAT) Shows Activity In Treatment Of Cancer
© 2011 Galectin Therapeutics 24 Our Drug GM-CT-01 (DAVANAT ® ) Shows Activity In Treatment Of Cancer Clinical studies (Phase 1 and 2 clinical trials) showed activity of treatment of metastatic colorectal cancer Phase 2 trial of 5-FU plus GM-CT-01 in line 3/4 therapy of metastatic colorectal cancer s
Slide 25: GM-CT-01 Reduces 5-FU Chemotherapy Related Side Effects
© 2011 Galectin Therapeutics 25 GM-CT-01 Reduces 5-FU Chemotherapy Related Side Effects Simultaneous improved efficacy with reduction in side effects of standard chemotherapy would be desirable in cancer therapeutics Data on 5-FU+GM-CT-01 compiled from patients receiving full dose therapy in studies
Slide 26: Development Approach In Colorectal Cancer
© 2011 Galectin Therapeutics 26 Development Approach In Colorectal Cancer Studies demonstrate potential utility of galectin inhibitors in combination with chemotherapy in cancer FDA has confirmed that preclinical and clinical data are adequate to proceed with large clinical trials Our colorectal can
Slide 27: Registration And Marketing GM-CT-01 In Colombia And Latin America
© 2011 Galectin Therapeutics 27 Registration And Marketing GM-CT-01 In Colombia And Latin America The government of Colombia, and oncology key opinion leaders in that country, expressed an interest in making GM-CT-01 available for use in Colombia for patients with metastatic colorectal cancer Equall
Slide 28: Goals for Cancer Chemotherapy Program
© 2011 Galectin Therapeutics 28 Goals for Cancer Chemotherapy Program Receive approval, market and sell GM-CT-01 in Colombia for use in combination with 5-FU in metastatic colorectal cancer Pursue post-marketing clinical trials in Colombia to acquire additional data on use of GM-CT-01
Slide 29: Disease Area Development Programs
© 2011 Galectin Therapeutics 29 Disease Area Development Programs Cancer Fibrosis Liver Fibrosis Chemotherapy Immunotherapy GALECTINS
Slide 30: Enhancing Anti-Tumor Immunity Is A Promising Effect Of Blocking Galectins
© 2011 Galectin Therapeutics 30 Enhancing Anti-Tumor Immunity Is A Promising Effect Of Blocking Galectins Tumor cell invasion: extracellular matrix adhesion & detachment Stromal cell function Metastasis: cell invasion and migration Angiogenesis Tumor immunity
Slide 31: Development Program In Cancer Immunotherapy
© 2011 Galectin Therapeutics 31 Development Program In Cancer Immunotherapy Galectin proteins secreted by tumor cells are directly responsible for inhibiting the ability of immune cells to kill tumors We have shown that GM-CT-01 inhibits galectin proteins and restores the ability of immune cells to
Slide 32: Blocking Galectins Enhances Tumor Killing By Immune System
© 2011 Galectin Therapeutics 32 Cytotoxicity Tumor-Specific Cytotoxic T-Cell Lymphocytes Blocking Galectins Enhances Tumor Killing By Immune System This mechanism is important in cancer treatment, but can also be used to boost the activity of tumor vaccines Tumor Cells
Slide 33: GM-CT-01 In Tumor Immunotherapy
© 2011 Galectin Therapeutics 33 GM-CT-01 In Tumor Immunotherapy This mechanism may boost the activity of tumor vaccines, and may be important generally in cancer treatment A Phase study is scheduled to begin Q3 2011 Patients with advanced metastatic melanoma Treatment Regimen: tumor-specific peptide
Slide 34: Goals for Tumor Vaccine Program
© 2011 Galectin Therapeutics 34 Goals for Tumor Vaccine Program Initiate clinical trial in patients with metastatic melanoma vaccine (Q3 2011) Seek collaborative programs with companies developing tumor vaccines
Slide 35: Pipeline
Pre-Clinical Phase 1 Phase 2 Phase 3 Registration Submitted © 2011 Galectin Therapeutics 35 Pipeline Colorectal Cancer GM-CT-01 International (Colombia) United States Tumor Vaccine GM-CT-01 Liver Fibrosis GM-CT-01 GM-CT-02 GM-MD-01 GM-MD-02
Slide 36: Condensed Balance Sheet
36 © 2011 Galectin Therapeutics Condensed Balance Sheet March 31, 2011 Assets (in 000’s) Cash and cash equivalents $ 6,948 Total assets $ 7,124 Liabilities and Stockholders Equity (Deficit) Accounts payable and accrued expenses $ 364 Deferred revenue Warrant liabilities Total liabilities Series B-1
Slide 37: Galectin Therapeutics Highlights
37 © 2011 Galectin Therapeutics Galectin Therapeutics Highlights Leader in galectin science and drug development with a pipeline of novel and proprietary carbohydrate-based drug compounds that inhibit galectins Galectins are implicated in a wide variety of serious disease. Active programs in liver f
Slide 38: Thank you for your attention
Annual Stockholders Meeting Thank you for your attention